Zepzelca
Payments companies reported to CMS as associated with Zepzelca. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Zepzelca, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Zepzelca
These are the largest totals companies reported as associated with Zepzelca. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Firas Badin | Lexington, KY | Hematology & Oncology | $270,493.34 |
| Joshua Sabari | New York, NY | Hematology & Oncology | $209,214.04 |
| Fadi Braiteh | Las Vegas, NV | Medical Oncology | $173,460.18 |
| Mark Socinski | Orlando, FL | Hematology & Oncology | $161,070.66 |
| Devesh Pandya | Houston, TX | Hematology & Oncology | $140,381.47 |
| Hatim Husain | San Diego, CA | Internal Medicine | $136,240.65 |
| Neal Ready | Durham, NC | Medical Oncology | $134,087.02 |
| Edgardo Santos | Fort Lauderdale, FL | Hematology & Oncology | $133,078.38 |
| Suresh Ratnam | Mcallen, TX | Medical Oncology | $128,313.71 |
| Martin Dietrich | Rockledge, FL | Hematology & Oncology | $115,285.36 |
Prescribed Zepzelca?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.